The effects on neuroinflammation, i.e., microglia and CD8+ T-cells, as well as the effects on cognitive outcome, were dose-dependent, therefore arguing for the use of higher MTK doses in AD clinical trials compared to the approved asthma dose. The gene discussed is CD8A; the disease is asthma.